IFI35 polyclonal antibody

Acts as a signaling pathway regulator involved in innate immune system response. In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator NMI to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 and correlates with IFI35 dephosphorylation. In complex with NMI, inhibits virus-triggered type I interferon/IFN-beta production. In complex with NMI, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of the NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries. Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs to promote inflammation when actively released by macrophage to the extracellular space during cell injury and pathogen invasion. Macrophage-secreted IFI35 activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of proinflammatory cytokines.

9007-83-4

1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

IFI35; IFP35

P80217

Human, Mouse

Recombinant fusion protein of human IFI35 (NP_005524.2) .

Unconjugated

WB, IF/ICC

WB,1:500 - 1:2000|IF/ICC,1:50 - 1:100

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Unmodification

35kDa

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

For research use only, not for use in diagnostic procedure.

Unmodification